<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of carcinoid syndrome and tumor localization</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of carcinoid syndrome and tumor localization</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of carcinoid syndrome and tumor localization</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "carcinoid" has been generally applied to well-differentiated neuroendocrine tumors (NETs) originating in the digestive tract, lungs, or rare primary sites, such as the kidneys or ovaries. In modern use, the term carcinoid is still used to refer to well-differentiated NETs arising in the lung (typical or atypical carcinoids), but within the gastrointestinal tract, the term carcinoid has fallen out of favor, and the World Health Organization (WHO) preference is for the term "NET." Regardless of site, the term "neuroendocrine carcinoma" is usually assigned to high-grade or poorly differentiated NETs. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Pathology, tumor classification, and nomenclature'</a>.)</p><p>NETs can present in several different ways:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>As a result of carcinoid syndrome</strong> – Chronic flushing and/or diarrhea are the typical manifestations of carcinoid syndrome, which is the result of secretion of serotonin and other vasoactive substances into the systemic circulation. Carcinoid syndrome is primarily associated with metastatic tumors originating in the midgut (distal small intestine and proximal colon). In contrast, hindgut (distal colorectal) and foregut (gastroduodenal, lung) NETs uncommonly produce carcinoid syndrome. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging", section on 'Presenting signs and symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>As a result of tumor growth</strong> – Small bowel NETs may cause chronic/recurrent abdominal pain, occasionally leading to bowel obstruction. Metastatic tumors in the liver can cause right upper quadrant pain, hepatomegaly, and early satiety. (See  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Jejunoileal small bowel tumors'</a> and  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>As an incidental finding</strong> – Many NETs are discovered during endoscopic or radiographic procedures planned for other purposes; this is especially true of NETs of the stomach and rectum.</p><p></p><p>This review will focus on the diagnosis of carcinoid syndrome and the localization/staging of well-differentiated NETs. Clinical and pathologic characteristics of NETs, treatment and prognosis of localized NETs, clinical manifestations and treatment of carcinoid syndrome, and treatment options for advanced metastatic gastrointestinal NETs are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Clinical presentation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">BIOCHEMICAL TESTING FOR CARCINOID SYNDROME</span><span class="headingEndMark"> — </span>Carcinoid syndrome is the result of secretion of serotonin and other vasoactive substances into the systemic circulation in the setting of a neuroendocrine tumor, most often a small bowel primary tumor with liver metastases. Hormone measurements in the blood and/or urine can serve an important role in identifying and following patients with carcinoid syndrome. In general, nonhormonal peptide biomarkers (eg, chromogranin A [CgA]) markers are less useful. (See  <a class="medical medical_review" href="/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p>The presence of carcinoid syndrome is usually considered when a patient has suggestive symptoms, such as otherwise unexplained chronic severe diarrhea and/or flushing. Clinical features of carcinoid syndrome other than flushing and diarrhea are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p class="headingAnchor" id="H1892378690"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Other conditions should be considered in the differential diagnosis, however:</p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis for flushing, for example, includes physiologic events, drugs, and a number of diseases other than carcinoid syndrome  (<a class="graphic graphic_table graphicRef78237" href="/d/graphic/78237.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/2782.html" rel="external">"Approach to flushing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis for diarrhea is broad. (See  <a class="medical medical_review" href="/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a>.)</p><p></p><p>In addition to the well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract that cause carcinoid syndrome, other well-differentiated NETs arising in the pancreas may cause severe diarrhea, including gastrinomas and VIPomas. (See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p>Assay of hormonal biomarkers can help in the differential diagnosis.</p><p class="headingAnchor" id="H1491132674"><span class="h2">Hormonal markers</span></p><p class="headingAnchor" id="H1465389147"><span class="h3">Blood serotonin concentration</span><span class="headingEndMark"> — </span>We do not recommend measurement of blood serotonin levels as a standard diagnostic test for carcinoid syndrome. Various serotonin assays have been described in the literature, including whole blood serotonin, platelet-rich plasma serotonin, and platelet-poor plasma serotonin assays. However, the sensitivities and specificities of these assays are not well established. In one report, the mean fasting blood serotonin concentration in normal subjects ranged from 71 to 310 ng/mL (0.4 to 1.8 micromol/L). Ten patients with carcinoid syndrome had markedly elevated values, from 790 to 4500 ng/mL (4.5 to 25.5 micromol/L); of these, two had normal urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion [<a href="#rid1">1</a>]. Notably, false-positive serotonin tests may occur due to release of platelet serotonin in stored blood samples, as well as from the ingestion of tryptophan/serotonin-rich foods [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h3">Urinary excretion of 5-HIAA</span><span class="headingEndMark"> — </span>A preferred initial diagnostic test for carcinoid syndrome is to measure 24-hour urinary excretion of 5-HIAA, which is the end product of serotonin metabolism  (<a class="graphic graphic_figure graphicRef51368" href="/d/graphic/51368.html" rel="external">figure 1</a>). This test has a sensitivity of over 90 percent and a specificity of 90 percent for carcinoid syndrome [<a href="#rid3">3</a>]. Sensitivity is low in patients with NETs without carcinoid syndrome [<a href="#rid4">4</a>].</p><p>False-positive results may be induced by the ingestion of certain drugs and tryptophan/serotonin-rich foods  (<a class="graphic graphic_table graphicRef79968" href="/d/graphic/79968.html" rel="external">table 2</a>). These foods should be avoided for three days prior to urine collection [<a href="#rid5">5</a>].</p><p>Measurement of urinary excretion of 5-HIAA is generally most useful in patients with primary midgut (jejunoileal, appendiceal, ascending colon) NETs, which produce the highest levels of serotonin. Foregut (gastroduodenal, bronchus) and hindgut (transverse, descending, and sigmoid colon, rectum, genitourinary) NETs only rarely secrete serotonin; they lack the enzyme dopa decarboxylase and cannot convert 5-hydroxytryptophan (5-HT) into serotonin and, therefore, into 5-HIAA  (<a class="graphic graphic_figure graphicRef51368" href="/d/graphic/51368.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. These tumors may produce 5-HT (and histamine) instead of serotonin. However, there is no commercially available assay for urinary 5-HT.</p><p>The normal rate of 5-HIAA excretion ranges from 2 to 8 mg/day (10 to 42 micromol/day). Values of up to 30 mg/day (157 micromol/day) may be found in patients with malabsorption syndromes, such as celiac and Whipple's disease, as well as after the ingestion of large amounts of tryptophan- or serotonin-rich foods  (<a class="graphic graphic_table graphicRef79968" href="/d/graphic/79968.html" rel="external">table 2</a>). Although many patients with carcinoid syndrome have similar modest elevations, some have values for urinary 5-HIAA excretion above 100 mg/day (523 micromol/day). In one study, for example, urinary 5-HIAA excretion in patients with carcinoid syndrome ranged from 99 to 2070 mg/day (518 to 10,826 micromol/day) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H1511485927"><span class="h3">Plasma 5-HIAA concentration</span><span class="headingEndMark"> — </span>Plasma 5-HIAA measurement is a reasonable option, particularly for patients who have difficultly providing 24-hour urine specimens, although published experience with this assay is confined to a small number of institutions, and this test has yet to be validated in large clinical series.</p><p>Plasma 5-HIAA levels can be obtained from several laboratories, and reportedly correlate closely with urine 5-HIAA [<a href="#rid7">7-9</a>]. In one study of 115 NET patients, levels of fasting plasma 5-HIAA correlated very closely with levels of urine 5-HIAA (p &lt;0.0001) [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3218067494"><span class="h3">Gastrin and VIP</span><span class="headingEndMark"> — </span>As noted above, some functional pancreatic neuroendocrine tumors (notably, gastrinomas and VIPomas) can be associated with severe diarrhea. In such cases, assays to 5-HIAA may be negative, but serum levels of gastrin and vasointestinal polypeptide (VIP) may be elevated, and aid in the differential diagnosis. (See  <a class="medical medical_review" href="/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Hormones associated with pancreatic NETs'</a>.)</p><p class="headingAnchor" id="H430178679"><span class="h2">Nonhormonal markers</span></p><p class="headingAnchor" id="H438190515"><span class="h3">Chromogranin concentration</span><span class="headingEndMark"> — </span>Due to its relatively low specificity, we do not recommend the use of CgA as a screening test for the diagnosis of a NET or carcinoid syndrome. CgA may be an appropriate tumor biomarker for patients with an established diagnosis of advanced NET in order to assess disease progression, response to therapy, or, in some cases, recurrence after surgical resection. (See  <a class="medical medical_review" href="/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Chromogranin A (CgA)'</a>.)</p><p>Chromogranins (designated as chromogranin A [CgA], chromogranin B [CgB], and chromogranin C [CgC]) are proteins that are stored and released with peptides and amines in a variety of neuroendocrine tissues. Well-differentiated NETs, including carcinoids, are associated with elevated blood concentrations of chromogranins, which increase with larger tumor burden [<a href="#rid5">5,10-12</a>]. CgB and CgC are less sensitive indicators of NETs as compared with CgA [<a href="#rid13">13</a>].</p><p>Despite a high volume of published studies evaluating multiple circulating nonhormonal tumor markers like CgA in NETs, consensus-based guidelines have increasingly de-emphasized their role in clinical care for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Levels of CgA secretion vary on a day-by-day basis in healthy subjects and those with NETs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Food intake also increases CgA levels [<a href="#rid14">14,15</a>]. False-positive elevations of CgA can be present in a number of other conditions, including atrophic gastritis  (<a class="graphic graphic_table graphicRef73287" href="/d/graphic/73287.html" rel="external">table 3</a>). They are especially common in patients who are taking a proton pump inhibitor [<a href="#rid16">16-18</a>]. As a result, CgA is a relatively nonspecific marker for NETs [<a href="#rid4">4,5,19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A recognized international standard for CgA assay is not available, and multiple CgA tests exist that use different assays, have widely divergent normal thresholds, and varying degrees of accuracy [<a href="#rid20">20</a>].</p><p></p><p>Sensitivity is limited for localized disease. Test performance is better with advanced disease and varies according to disease burden, and the specific cutoff value [<a href="#rid11">11,21</a>]. In general, serial measurements of CgA and/or other nonhormonal tumor markers are most useful in patients with metastatic NETs and highly elevated levels of the marker, which are more likely to be true-positives than false-positives. In such patients, serial assay of CgA levels may be a reasonable indicator of disease activity and response to antitumor therapy. Whenever we do measure tumor marker levels, we usually obtain them in conjunction with radiographic imaging, typically every 6 to 12 months. (See  <a class="medical medical_review" href="/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Chromogranin A (CgA)'</a> and  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Chromogranin A'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">TUMOR LOCALIZATION AND STAGING</span></p><p class="headingAnchor" id="H757636589"><span class="h2">Tumors originating in intestinal tract</span><span class="headingEndMark"> — </span>Carcinoid syndrome is primarily associated with metastatic neuroendocrine tumors (NETs) that originate in the small intestine or proximal colon. Vasoactive peptides that are produced by localized intestinal NETs are inactivated in the portal circulation and, thus, do not result in carcinoid syndrome. The liver is the most common distant metastatic site. Imaging studies should, therefore, focus on the abdomen and pelvis. Computed tomography (CT), magnetic resonance imaging (MRI), and diagnostic imaging using radiolabeled somatostatin analogs (SSAs; indium-111 pentetreotide [111-In pentetreotide; OctreoScan] and <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> [68-Ga DOTATATE]) are the primary imaging modalities used to identify NETs.</p><p class="headingAnchor" id="H31868282"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>CT scans are noninvasive and readily available. Multiphasic contrast-enhanced CT is recommended for evaluation of all patients with NETs, with the exception of tumors with a very low probability of spread, such as most type 1 and 2 gastric NETs or small (&lt;1 to 2 cm) superficial (T1) rectal NETs [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Staging and treatment of localized tumors'</a>.)</p><p>Most NET liver metastases are highly vascular, but approximately 6 to 20 percent are hypovascular [<a href="#rid24">24</a>]. Hypervascular metastases may appear isodense with the liver on a noncontrasted study. Following the injection of intravenous contrast, most NETs enhance with iodinated contrast during the early arterial phase (approximately 20 seconds after contrast injection), with washout during the portal venous imaging phase (approximately 70 seconds after contrast injection) [<a href="#rid24">24,25</a>]. Arterial phase and portal venous phase sequences maximize the conspicuity of liver metastases compared with the surrounding normal liver parenchyma  (<a class="graphic graphic_diagnosticimage graphicRef52935" href="/d/graphic/52935.html" rel="external">image 1</a>).</p><p>The ability of CT to localize the site of the primary tumor in patients with carcinoid syndrome is variable:</p><p class="bulletIndent1"><span class="glyph">●</span>NETs originating in the jejunum and ileum are often difficult to identify on CT because of their small size. However, multiphasic helical CT performed with neutral oral contrast and multiplanar reformations can improve detection [<a href="#rid24">24</a>]. Arterial phase imaging can aid in detection of these early enhancing lesions. Small intestinal NETs often produce mesenteric masses with dense desmoplastic fibrosis, either due to direct extension of primary tumors into the mesentery or due to mesenteric lymph node metastases  (<a class="graphic graphic_diagnosticimage graphicRef78186" href="/d/graphic/78186.html" rel="external">image 2</a>). The classic finding on CT is a mass-like process with soft tissue "spokes" radiating into the mesenteric fat toward the small bowel, often causing retraction of the bowel with angulation and tethering. The central mass may or may not be calcified. The differential diagnosis includes sclerosing mesenteritis. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Small intestine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appendiceal NETs may not be seen on CT because of their small size [<a href="#rid24">24</a>]. The scan may only show features of appendicitis, such as diffuse thickening of the appendix or periappendiceal fat stranding. A larger tumor may present as a soft tissue mass in the appendix, with or without calcification. (See  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Staging and prognosis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonic NETs tend to be large (&gt;2 cm) and more frequently involve the cecum and ascending colon. CT cannot differentiate a colonic NET from the more common adenocarcinoma since both present as circumferential thickening or polypoid masses and may have adjacent lymphadenopathy [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Colon'</a>.)</p><p></p><p class="headingAnchor" id="H31868289"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>MRI may represent the most sensitive method for detection of liver metastases. In one study of 64 patients with metastatic gastrointestinal NETs, multiphasic MRI detected more hepatic lesions than either CT or 111-In pentetreotide [<a href="#rid26">26</a>]. As a result of this greater sensitivity for liver metastases, some clinicians prefer MRI over CT for assessing the status of the liver in patients with NETs [<a href="#rid27">27</a>]. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Cross-sectional imaging'</a>.)</p><p>However, even MRI can significantly underestimate the total tumor burden, especially when lesions are small. In a study comparing preoperative imaging with thin-section pathology mapping, the accuracy for detecting liver metastases was only 49 percent for MRI [<a href="#rid28">28</a>].</p><p>As with CT scans, early arterial phase imaging following the injection of contrast is critical for the detection of small hypervascular liver metastases. In a study of 37 patients with liver metastases from gastroenteropancreatic NETs, the most sensitive sequences for detection of liver metastases were hepatic arterial phase and fast spin-echo T2-weighed images [<a href="#rid29">29</a>]. In another study comparing two MRI contrast agents, the delayed hepatobiliary phase using <a class="drug drug_general" data-topicid="9085" href="/d/drug information/9085.html" rel="external">gadoxetate</a> (Eovist) contrast provided the highest contrast-to-noise ratio as well as the highest levels of interobserver agreement on tumor diameter [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H31868296"><span class="h3">Somatostatin receptor-based imaging</span><span class="headingEndMark"> — </span>Most well-differentiated NETs express high levels of somatostatin receptors (SSTRs) and can therefore be imaged with radiolabeled SSAs. These scans allow for whole body imaging. They also provide information on SSTR expression, which has important therapeutic implications regarding use of cold and radiolabeled SSAs. The first imaging technique to visualize SSTR-expressing tumors used 111-In pentetreotide to produce a scintigraphic image (OctreoScan). The accuracy of 111-In pentetreotide improved with the addition of single-photon emission CT (SPECT) to planar imaging  (<a class="graphic graphic_diagnosticimage graphicRef72923" href="/d/graphic/72923.html" rel="external">image 3</a>) [<a href="#rid31">31,32</a>]. More recently, several positron emission tomography (PET) tracers for SSTR imaging have emerged (such as 68-Ga DOTATATE and 68-Ga DOTATOC), which in combination with CT, improve the detection and staging of NETs [<a href="#rid33">33</a>]. These novel PET modalities offer higher spatial resolution than conventional 111-In pentetreotide scanning and are associated with improved sensitivity for detection of small lesions, including occult primary tumors  (<a class="graphic graphic_diagnosticimage graphicRef81388" href="/d/graphic/81388.html" rel="external">image 4</a>). In our view (and that of others [<a href="#rid34">34</a>]), 68-Ga DOTATATE or 68-Ga DOTATOC PET/CT, where available, is preferred over conventional 111-In pentetreotide scanning for tumor localization. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site", section on 'Initial workup'</a> and  <a class="medical medical_review" href="/d/html/2516.html" rel="external">"Diagnosis and staging of small bowel neoplasms", section on 'Somatostatin receptor-based imaging'</a>.)</p><p>Of note, poorly differentiated neuroendocrine carcinomas generally express fewer SSTRs and are not routinely evaluated with SSTR imaging [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H432325"><span class="h3">Endoscopy</span><span class="headingEndMark"> — </span>Upper and lower endoscopy (with attention to the terminal ileum) should be performed for the evaluation of metastatic NET if the primary site cannot be established through imaging studies. Other options include CT enterography. Although video capsule endoscopy has been used to detect the primary site in metastatic NETs, we do not recommend this study given several reports of obstruction following ingestion of the video capsule [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2663952178"><span class="h2">Lung neuroendocrine tumors</span><span class="headingEndMark"> — </span>Uncommonly, lung NETs can present with carcinoid syndrome, even in the absence of hepatic metastases. As with intestinal primaries, cross-sectional imaging and diagnostic imaging with radiolabeled SSAs can be used to localize well-differentiated lung NETs (bronchial carcinoids). These tumors tend to be centrally located endobronchial lesions; however, approximately 20 percent arise peripherally and present as a well-circumscribed solitary pulmonary nodule  (<a class="graphic graphic_diagnosticimage graphicRef61692" href="/d/graphic/61692.html" rel="external">image 5</a>). (See  <a class="medical medical_review" href="/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging", section on 'Clinical syndromes related to peptide production'</a>.)</p><p class="headingAnchor" id="H424998551"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H639612617"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/86735.html" rel="external">"Patient education: Carcinoid syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of carcinoid syndrome due to a neuroendocrine tumor involving the gastrointestinal tract may be suspected when a patient has otherwise unexplained diarrhea or flushing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, other diagnoses must be considered. The differential diagnosis of flushing, for example, includes physiologic events, drugs, and a number of diseases other than carcinoid syndrome  (<a class="graphic graphic_table graphicRef78237" href="/d/graphic/78237.html" rel="external">table 1</a>). Moreover, other NET types arising in the pancreas (eg, VIPomas) can cause severe chronic diarrhea. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to biochemical testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urinary 5-HIAA</strong> – The most useful initial diagnostic test for carcinoid syndrome is to measure 24-hour urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA), which is the end product of serotonin metabolism  (<a class="graphic graphic_figure graphicRef51368" href="/d/graphic/51368.html" rel="external">figure 1</a>). Depending on the cutoff value used, this test has a high sensitivity and high specificity for carcinoid syndrome but requires strict avoidance of foods containing serotonin and tryptophan as well as certain drugs for three days prior to the urine collection  (<a class="graphic graphic_table graphicRef79968" href="/d/graphic/79968.html" rel="external">table 2</a>). (See <a class="local">'Urinary excretion of 5-HIAA'</a> above.)</p><p></p><p class="bulletIndent2">Measurement of urinary 5-HIAA excretion is generally not useful in foregut (gastroduodenal, lung) NETs, which often lack aromatic amino acid decarboxylase. In this setting, we would pursue imaging studies to search for a NET.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum chromogranin A</strong> – Due to its relatively low specificity, we do not recommend the use of serum chromogranin A (CgA) as a screening test for the diagnosis of carcinoid syndrome. (See <a class="local">'Chromogranin concentration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor localization</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Once the biochemical diagnosis of carcinoid syndrome is confirmed, usually by an elevated 24-hour excretion of 5-HIAA, the tumor must be localized. (See <a class="local">'Tumor localization and staging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two techniques, standard cross-sectional imaging and somatostatin receptor-based imaging, have a complementary role in tumor localization:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For the diagnostic workup of carcinoid syndrome, we generally perform helical, contrast-enhanced, triple-phase CT scans of the abdomen and pelvis. (See <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent3">Contrast-enhanced MRI of the abdomen and pelvis is an acceptable alternative and is preferred by some clinicians because of its greater sensitivity for liver metastases. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Most well-differentiated NETs express high levels of somatostatin receptors (SSTRs) and can therefore be imaged with radiolabeled somatostatin analogs which can assist in identifying an otherwise occult primary site. Where available, functional imaging with <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> positron emission tomography (PET)/CT is preferred over indium-111 pentetreotide (OctreoScan) due to its greater sensitivity. (See <a class="local">'Somatostatin receptor-based imaging'</a> above.)</p><p></p><p class="bulletIndent3">Poorly differentiated neuroendocrine carcinomas generally express fewer SSTRs and are not routinely evaluated with SSTR imaging.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upper and lower endoscopy (with attention to the terminal ileum) should be performed for the evaluation of metastatic NET if the primary site cannot be established through imaging studies. (See <a class="local">'Endoscopy'</a> above.)</p><p></p><p class="headingAnchor" id="H1685630081"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stephen Goldfinger, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Richter G, Stöckmann F, Conlon JM, Creutzfeldt W. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology 1986; 91:612.</a></li><li><a class="nounderline abstract_t">Allen KR, Degg TJ, Anthoney DA, Fitzroy-Smith D. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples. Ann Clin Biochem 2007; 44:300.</a></li><li><a class="nounderline abstract_t">Sjöblom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol 1988; 23:779.</a></li><li><a class="nounderline abstract_t">O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90:194.</a></li><li><a class="nounderline abstract_t">Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.</a></li><li><a class="nounderline abstract_t">Feldman JM. Carcinoid tumors and syndrome. Semin Oncol 1987; 14:237.</a></li><li><a class="nounderline abstract_t">Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem 2016; 53:554.</a></li><li><a class="nounderline abstract_t">Tellez MR, Mamikunian G, O'Dorisio TM, et al. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas 2013; 42:405.</a></li><li><a class="nounderline abstract_t">Carling RS, Degg TJ, Allen KR, et al. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002; 39:577.</a></li><li><a class="nounderline abstract_t">Eriksson B, Arnberg H, Oberg K, et al. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990; 122:145.</a></li><li><a class="nounderline abstract_t">Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.</a></li><li><a class="nounderline abstract_t">Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644.</a></li><li><a class="nounderline abstract_t">Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49.</a></li><li><a class="nounderline abstract_t">Granberg D, Stridsberg M, Seensalu R, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84:2712.</a></li><li><a class="nounderline abstract_t">Fossmark R, Jianu CS, Martinsen TC, et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43:20.</a></li><li><a class="nounderline abstract_t">Pregun I, Herszényi L, Juhász M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84:22.</a></li><li><a class="nounderline abstract_t">Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011; 105:1173.</a></li><li><a class="nounderline abstract_t">Vezzosi D, Walter T, Laplanche A, et al. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 2011; 26:94.</a></li><li><a class="nounderline abstract_t">Di Giacinto P, Rota F, Rizza L, et al. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol 2018; 2018:8126087.</a></li><li><a class="nounderline abstract_t">Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40:111.</a></li><li><a class="nounderline abstract_t">Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007; 14:473.</a></li><li><a class="nounderline abstract_t">Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90:167.</a></li><li class="breakAll">Consensus-based guidelines from the National Comprehensive Cancer Network are available online at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on March 29, 2016).</li><li><a class="nounderline abstract_t">Ganeshan D, Bhosale P, Yang T, Kundra V. Imaging features of carcinoid tumors of the gastrointestinal tract. AJR Am J Roentgenol 2013; 201:773.</a></li><li><a class="nounderline abstract_t">Paulson EK, McDermott VG, Keogan MT, et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998; 206:143.</a></li><li><a class="nounderline abstract_t">Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70.</a></li><li><a class="nounderline abstract_t">Pisegna JR, Doppman JL, Norton JA, et al. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38:1318.</a></li><li><a class="nounderline abstract_t">Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think... Ann Surg 2010; 251:307.</a></li><li><a class="nounderline abstract_t">Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003; 180:121.</a></li><li><a class="nounderline abstract_t">Morse B, Jeong D, Thomas K, et al. Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements? Pancreas 2017; 46:1219.</a></li><li><a class="nounderline abstract_t">Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.</a></li><li><a class="nounderline abstract_t">Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59:565.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a class="nounderline abstract_t">Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59:66.</a></li><li><a class="nounderline abstract_t">Strosberg J, Nasir A, Coppola D, et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40:1262.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol 2007; 21:113.</a></li></ol></div><div id="topicVersionRevision">Topic 2622 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2426155" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456301" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3227292" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical presentation and prognosis of gastrointestinal carcinoid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19713711" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20217257" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2442815" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Carcinoid tumors and syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438520" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160483" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12564839" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2316306" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513802" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chromogranin A: is it a useful marker of neuroendocrine tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15104570" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891024" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443665" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Plasma chromogranin A in patients with multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18938772" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21304238" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of proton-pump inhibitor therapy on serum chromogranin a level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989216" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21574156" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057604" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349414" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17639060" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077417" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077417" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24059366" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Imaging features of carcinoid tumors of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423664" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Carcinoid metastases to the liver: role of triple-phase helical CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625361" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325191" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010089" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think...</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490490" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28902795" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604127" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616879" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712231" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025982" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368957" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299616" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
